McDonnell Boehnen Hulbert & Berghoff LLP partner John Conour, Ph.D. authors a February 1, 2019 Life Science Leader article entitled, “Why Patent Protection Is Key To Commercializing Repurposed Drugs.” If you’ve been involved in any aspect of drug development in your career, it’s likely you are aware that, on average, only 1 in 10 therapeutic candidates that enter Phase 1 clinical trials is approved. Consequently, the industry is littered with abandoned, shelved drugs, or drugs simply listed as “failures.” View the article
